期刊文献+

凝血和抗凝及纤溶功能改变在进展型脑梗死患者中的临床意义 被引量:9

Coagulation,anticoagulation and fibrinolytic function changes in patients with progressive cerebral infarction
在线阅读 下载PDF
导出
摘要 目的研究进展型脑梗死患者凝血、抗凝和纤溶系统功能指标的变化,探讨进展型脑梗死的发病机制,为其临床早期诊断和治疗提供依据。方法对比检测了209例进展型脑梗死患者与209例完全型脑梗死患者血浆凝血酶原时间、凝血酶时间、部分凝血活酶时间、纤维蛋白原、血小板聚集率、血管性血友病因子含量、抗凝血酶、组织型纤溶酶原激活物及纤溶酶原激活物抑制剂-1活性水平。结果与完全型脑梗死患者比较,进展型脑梗死患者的血浆凝血酶原时间、凝血酶时间、部分凝血活酶时间显著缩短,抗凝血酶、组织型纤溶酶原激活物水平显著降低,而纤维蛋白原、血小板聚集率、血管性血友病因子、纤溶酶原激活物抑制剂-1水平显著升高(P<0.01)。结论进展型脑梗死患者存在着明显的高凝血和较低的抗凝和纤溶活性。 Objective To early diagnose progressive cerebral infarction and have more time in thrombolytic treatment, and to discuss, the unique clinical classification and laboratory test of progressive cerebral infarction. Methods The exploratory research was done in 209 cases with progressive cerebral infarction. Prothrombin time (PT), activated partial thromboplastin time (APIT), thrombin time (TF), fibrinogen (Fib), yon Willebrand factor(vWF), platelet aggregation test (PAgT), anti-thrombin activity (AT), tissue-type plasminogen activator (t-PA) and its inhibitor (PAI-1) in the patients were assayed. Results PT, APTT,TT, AT-A and t-PA in the patients with progressive cerebral infarction were significant shorter or less than that in patients with complete cerebral infarction. But the concentration of Fib, vWF, PAgT and PAI-1 in the patients were significant higher than that in patients with complete cerebral infarction. Conclusion The function of anticoagulation and fibrinolysis in the patients with progressive cerebral infarction are significantly lower than that in patients with complete cerebral infarction.
出处 《中华老年心脑血管病杂志》 CAS 北大核心 2005年第6期401-403,共3页 Chinese Journal of Geriatric Heart,Brain and Vessel Diseases
关键词 脑梗塞 血液凝固 抗凝血酶类 纤溶酶原激活物抑制物 组织型纤溶酶原激活物 brain infarction blood coagulation antithrombins plasminogen activator inhibitor 1 tissue plasminogen activator
作者简介 吕涌涛,男,1963年10月生。山东省济南市人,副主任医师,硕士,从事神经内科专业。
  • 相关文献

参考文献3

二级参考文献9

  • 1Sharabi Y, Doolman R, Rosenthal T, et al. Homocysteine levels in hypertensive patients with a history of cardiac or cerebral atherothrombotic events[J]. Am J Hypertens, 1999,12:766-771.
  • 2Stchouwur DA, Weijenberg PM, Vanden B, et al. Serum homocysteine and risk of coronary heart disease and cerebrovascular disease in elderly men, a 10-year-follow-up[J]. Arterioscler Thromb Vasc Biol,1998,18 : 1895 -1901.
  • 3Folsom AR, Aleksic N, Park E, et al. Prospective study of fibrinolytic factors and incident coronary heart disease:The Atherosclerosis Risk in Communities (ARIC) Study [J]. Arterioscler Thromb Vasc Biol,2001,21:611-617.
  • 4Lindgren A, Lindoff C, Norrving B, et al. Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients[J]. Stroke,1996,27:1066-1071.
  • 5Johansson L, Jansson JH, Boman K, et al. Tissue plasminogen activator, plasminogen activator inhibitor-l, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a frrst stroke[J]. Stroke,2000,31:26-32.
  • 6Tofler GH, D' Agostino RB, Jacques PF, et al. Association between increased homocysteine levels and impaired fibrinolytic potential: potential mechanism for cardiovascular risk [J]. Thromb Haemost, 2002,88:799-804.
  • 7Muscari A, Mele MC, Bastagli L, et al. Conditional risk factors in men with previous myocardial infarction: relevance of C 3 and homocysteine [J]. Acta Cardiol, 2001,56: 303-311.
  • 8Glowinska B, Urban M, Koput A, et al. New atherosclerosis risk factom in obese, hypertensive and diabetic children and adolescents [J].Atherosclerosis, 2003,167:275-286.
  • 9李曦,谢英,周玉杰,张维君,洪昭光.同型半胱氨酸与冠心病关系的探讨[J].中华老年心脑血管病杂志,2002,4(6):378-380. 被引量:4

共引文献43059

同被引文献62

引证文献9

二级引证文献44

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部